HER2-Positive Breast Cancer

Treatment Options for HER2+ Breast Cancer Open to Multiple Lines of Therapy and Subgroups

October 20, 2020

Until recently, few options existed for patients with HER2-positive breast cancer who progressed on earlier lines of therapy. Recent approvals of 3 drug combinations offer new tools that may prolong life and control brain metastases across lines of therapy.

Stage Is Set for Exploring TNBC, HER2-Positive Settings at 38th Annual CFS

September 23, 2020

Delivering evidence-based state-of-the art cancer care in the management of hematologic and solid malignancies is the mainstay of the 38th Annual CFS®: Innovative Cancer Therapy for Tomorrow conference taking place virtually November 4 through 6, 2020.

Updated ALTERNATIVE Results Favor Dual HER2 Blockade in HER2+/HR+ Metastatic Breast Cancer

September 22, 2020

“Dual targeting of HER2-positive tumors with [trastuzumab] and [lapatinib] is beneficial because of differing mechanisms of action and because of the well-characterized synergistic interaction between them in HER2 [breast cancer] models."

Survival Improved With Tucatinib Regimen in HER2-Positive Metastatic Breast Cancer

September 21, 2020

Statistically significant and clinically meaningful improvements in both progression-free survival and overall survival were observed with the addition of tucatinib to trastuzumab and capecitabine as treatment of patients with HER2-positive metastatic breast cancer, irrespective of the presence of brain metastases.

HER2+ Breast Cancer Treatment Approaches Becomes More Individualized

September 16, 2020

In an interview with Targeted Oncology, Sara A. Hurvitz, MD, reviewed the 4 currently approved treatment options for patients with HER2-positive breast cancer and discussed how physicians could use the data to make treatment decisions in the adjuvant and neoadjuvant setting.

Current Breast Cancer Landscape and Targeted Therapies for HER2 Overexpression

September 16, 2020

Breast cancer is the most common cancer that affects women, with estimates that it will account for 30% of all new cancer diagnoses in women in 2020. As the most commonly overexpressed receptor in breast cancer, HER2 is amplified or overexpressed in about 15% of breast cancers, leading to dysregulated cell proliferation. This article explores the current breast cancer landscape, with a focus on emerging HER2-targeted therapies, and discusses the unmet needs within the treatment landscape.